Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria Ragip Ertas, MD, Kemal Ozyurt,

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

The natural history of soy allergy

Allergen immunotherapy: A practice parameter third update

Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials Zuo-Tao Zhao, MD, PhD, Chun-Mei Ji, M Pharm,

Responsiveness and minimal important difference of the urticaria control test Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Is 9 more than 2 also in allergic airway inflammation?

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial Marko Kalliomäki, MD, PhD,

Desensitization to Chemotherapeutic Agents

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Pavel Kolkhir, MD, Martin K

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Allergy testing in predicting outcome of open food challenge to peanut

The National Biome Initiative: An allergy perspective

The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria Tse Wen Chang, PhD, Christina Chen, BS, Chien-Jen.

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Peter M. Wolfgram, MD, David B. Allen, MD

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug–related urticaria and angioedema Marek L.

Repeated Episodes of Anaphylaxis with Normal Serum Tryptase but Elevated Levels of Urinary Prostaglandin D2 Phillip Lieberman, MD The Journal of Allergy.

Serum tryptase levels in atopic and nonatopic children

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

What are the best outcome measurements for atopic eczema

Phillip Lieberman, MD, David Golden, MD

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Christian Hennig, MD, Christine Happle, MD, Gesine Hansen, MD

Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A

Invasive fungal disease in autosomal-dominant hyper-IgE syndrome

Sharon Seth, MD, David A. Khan, MD

What is an “eosinophilic phenotype” of asthma?

Cephalosporin Side Chain Cross-reactivity

Jeffrey M. Harris, MD, PhD, Christopher R

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria Janine Gericke, PhD, Martin Metz, MD, Tatevik Ohanyan,

Real-life treatment of cholinergic urticaria with omalizumab

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Bruce G. Bender, PhD, Alex Pedan, PhD, Laleh T. Varasteh, RPh, MSF

One step forward, 2 steps back: The enigma of preschool wheeze

Risk of oral food challenges

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Sonja A. Grundmann, MD, Pia B. Hemfort, MD, Thomas A

George Philip, MD, Carolyn M

The natural history of IgE-mediated cow's milk allergy

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Measles and immunomodulation

The Editors' Choice Journal of Allergy and Clinical Immunology

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria Sridharan Soundararajan, PhD, Yoko Kikuchi, DVM, Kusumam Joseph, PhD,

Environmental factors and eosinophilic esophagitis

Lisa A. Beck, MD, Sarbjit Saini, MD

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

Advances in pediatric asthma in 2007

Safety and efficacy of repeated monthly carboplatin desensitization

Association between varicella zoster virus infection and atopic dermatitis in early and late childhood: A case-control study Jonathan I. Silverberg,

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria Ragip Ertas, MD, Kemal Ozyurt, MD, Emin Ozlu, MD, Yilmaz Ulas, MD, Atil Avci, MD, Mustafa Atasoy, MD, Tomasz Hawro, MD, Marcus Maurer, MD Journal of Allergy and Clinical Immunology Volume 140, Issue 6, Pages 1749-1751 (December 2017) DOI: 10.1016/j.jaci.2017.08.007 Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Relapse time in patients with normal (<100 IU/mL) and increased (>100 IU/mL) IgE levels (Kaplan-Meier plot). Time to relapse after discontinuation of omalizumab was shorter in CRs with increased baseline total IgE levels compared with patients with normal IgE levels (log-rank test: χ2 = 5.78, P = .016, n = 26). Journal of Allergy and Clinical Immunology 2017 140, 1749-1751DOI: (10.1016/j.jaci.2017.08.007) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions